Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men

Blood

Volumn 87, Issue 3, 1996, Pages 900-905

  Pollmächer, Thomas ^a   Korth, Carsten ^b   Mullington, Janet ^b   Schreiber, Wolfgang ^b   Sauer, Joachim ^b   Vedder, Helmut ^b   Galanos, Chris ^b   Holsboer, Florian ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALMONELLA ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL INFECTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM TEMPERATURE; SALMONELLA; SALMONELLOSIS; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030056892     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.900.bloodjournal873900     Document Type: Article

References (44)

1. Parrillo JE: Pathogenetic mechanisms of septic shock. New Engl J Med 328:1471, 1993
2. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. New Engl J Med 318:1481, 1988
3. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 338:1423, 1991
4. van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 89:4845, 1992
5. Pollmächer T, Schreiber W, Gudewill S, Vedder H, Fassbender K, Wiedemann K, Trachsel L, Galanos C, Holsboer F: Influence of endotoxin on nocturnal sleep in humans. Am J Physiol 264:R1077, 1993
6. Kuhns DB, Alvord WG, Gallin JI: Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 171:145, 1995
7. Wenzel RP: Anti-endotoxin monoclonal antibodies - a second look. N Engl J Med 326:1151, 1992
8. Warren HS, Danner RL, Munford RS: Anti-endotoxin monoclonal antibodies. N Engl J Med 326:1153, 1992
9. Fisher CJ, Dhainaut J-F, Pribble JP: A study evaluating the safety and efficacy of human recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Presented at the 13th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 23, 1993
10. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12, 1994
11. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771, 1994
12. Steward WP: Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 342:153, 1993
13. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hiral M, Kurosawa S, Mori M, Fukushima M: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76:1962, 1990
14. Mooney DP, Gamelli RL, O'Reilly M, Hebert JC: Recombinant human granulocyte colony-stimulating factor and pseudomonas burn wound sepsis. Arch Surg 123:1353, 1988
15. Iida J, Saiki I, Ishihara C, Azuma I: Protective activity of recombinant cytokines against sendai virus and herpes simplex virus (HSV) infections in mice Vaccine 7:229, 1989
16. Silver GM, Gamelli RL, O'Reilly M: The beneficial effect of granulocyte colony-stimulating factor (G-CSF) in combination with gentamicin on survival after pseudomonas burn wound infection. Surgery 106:452, 1989
17. Hebert JC, O'Reilly M, Gamelli RL: Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 125:1075, 1990
18. Lister PD, Gentry MJ, Preheim LC: Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 168:922, 1993
19. Toda H, Murata A, Matsuura N, Uda K, Oka Y, Tanaka N, Mori T: Therapeutic efficacy of granulocyte colony stimulating factor against rat cecal ligation and puncture model. Stem Cells 11:228, 1993
20. Görgen I, Hartung T, Leist M, Niehörster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 149:918, 1992
21. Hartung T, Döcke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of G-CSF treatment on ex vivo blood cytokine response in human volunteers. Blood 85.2482, 1995
22. Aschoff J: Circadian rhythms: General features and endocrinological aspects, in Krieger DT (ed): Endocrine Rhythms, New York, NY, Raven, 1979, p 1
23. Kräuchi K, Wirz-Justice A: Circadian rhythm of heat production, heart rate, and skin and core temperature under unmasking conditions in men. Am J Physiol 267:R819, 1994
24. Djeu JY, Serbousek D, Blanchard DK: Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood 76:1405, 1990
25. Porteu F, Nathan C: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599, 1990
26. McColl SR, Paquin R, Ménard C, Beaulieu AD: Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 176:593, 1992
27. Malyak M, Smith MF, Abel AA, Arend WP: Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1β. J Clin Immunol 14:20, 1994
28. Re F, Mengozzi M, Muzio M, Dinarello CA, Mantovani A, Colotta F: Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphonuclear cells. Eur J Immunol 23:570, 1993
29. de Haas M, Kerst JM, van der School E, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RHJ, von dem Borne AEGKr: Granulocyte colony-stimulating factor administration to healthy volunteers: Analysis of the immediate activating effects on circulating neutrophils. Blood 84:3885, 1994
30. Lantz M, Björnberg F, Olsson I, Richter J: Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 152:1362, 1994
31. Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach ICM, Kleijer M, von dem Borne AEGKr, van Oers RHJ: Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: Induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82:3265, 1993
32. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431, 1990
33. Ferrero E, Jiao D, Tsuberi BZ, Tesio L, Rong GW, Haziot A, Goyert SM: Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 90:2380, 1993
34. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, Arthur K, Dinarello CA, Cerami A, Wolff SM, Kufe DW, Wilmore DW: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280, 1988
35. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T: Tumor necrosis factor in man: Clinical and biological observations. Br J Cancer 56:803, 1987
36. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman WA: Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338:515, 1991
37. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxinemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548, 1993
38. de Groote D, Grau GE, Dehart I, Franchimont P: Stabilisation of functional tumor necrosis factor-α by its soluble TNF receptors. Eur Cytokine Netw 4:359, 1993
39. Mackensen A, Galanos C, Wehr U, Engelhardt R: Endotoxin tolerance: Regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 3:571, 1992
40. Zabel P, Wolter DT, Schönharting MM, Schade UF: Oxpentifylline in endotoxaemia. Lancet 2:1474, 1989
41. Yuo A, Kitagawa S, Ohsaka A, Ohta M, Miyazono K, Okabe T, Urabe A, Saito M, Takaku F: Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: Potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood 74:2144, 1989
42. Ohsaka A, Saionji K, Sato N, Mori T, Ishimoto K, Inamatsu T: Granulocyte colony-stimulating factor down-regulates the surface expression of the human leucocyte adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol 84:574, 1993
43. 2 integrins after trauma: A possible role for colony-stimulating factors. Clin Exp Immunol 92:477, 1993
44. Wright SD, Ramos RA, Hermanowski-Vosatka A, Rockwell P, Detmers PA: Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: Dependence on lipopolysaccharide binding protein and CD14. J Exp Med 173:1281, 1991